[{"id":"c5069877-91bb-4251-94b9-54a5d23f9ae6","acronym":"LuMIERE","url":"https://clinicaltrials.gov/study/NCT04939610","created_at":"2023-10-21T07:12:22.742Z","updated_at":"2025-02-25T14:40:52.491Z","phase":"Phase 1/2","brief_title":"A Study of 177Lu-FAP-2286 in Advanced Solid Tumors","source_id_and_acronym":"NCT04939610 - LuMIERE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FAP","pipe":" | ","alterations":" FAP expression","tags":["FAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FAP expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lutetium Lu 177 rofapitide tetraxetan (AAA614)"],"overall_status":"Recruiting","enrollment":" Enrollment 222","initiation":"Initiation: 07/30/2021","start_date":" 07/30/2021","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-02-14"}]